Released Mar 12, 2025, after the close
10-K filed Mar 12, 2025, 71 days after period end · 0001493152-25-010051
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.00K$1.00K derivedno prior Q4 2023 on file−99.8% vs Q3 2024
Net Income-$5.76M-$5.76M derivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$1,000N/M
Operating Incomederived-$2,697,000N/M
Operating Cash Flowderived-$3,545,000N/M
Free Cash Flowderived-$3,545,000N/M
Margins · derived
Gross margin100.0%
Operating margin-269700.0%
Net margin-575900.0%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $1.00K | — | — | — |
| Net Income | -$5.76M | -$6.15M | -$4.49M | -$7.95M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR